Companies ›Healthcare ›1501.HK

1501.HK — HKEX Medical Equipment, Supplies & Distribution

Shanghai INT Medical Instruments Co Ltd

HK$34,00

Open in Charts → Attach watcher ⌖

— —

HKD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

0,66 %

Op margin

25,5 %

ROE

11,0 %

Net margin

20,5 %

Debt / equity

0,36

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Shanghai INT Medical Instruments Co Ltd is a medical equipment and supplies company that generates revenue primarily through the production and distribution of medical devices and related healthcare products.

Business. Shanghai INT Medical Instruments Co Ltd (1501.HK) is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates primarily through a product-sale revenue model, focusing on the provision of medical devices and related supplies. Headquartered in Shanghai, the company is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryMedical Equipment, Supplies & Distribution

ActivityHealthcare Services & Equipment

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability→

11,0 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning 1501.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to 1501.HK. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Shanghai INT Medical Instruments Co Ltd (1501.HK) is a healthcare company engaged in the medical equipment, supplies, and distribution industry. The firm operates primarily through a product-sale revenue model, focusing on the provision of medical devices and related supplies. Headquartered in Shanghai, the company is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryMedical Equipment, Supplies & Distribution

ActivityHealthcare Services & Equipment

AI synthesis

GENERATED

Shanghai INT Medical Instruments Co Ltd maintains a conservative capital structure, with a debt-to-equity ratio of 0.36, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.26, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess liquidity. The company's free cash flow of 222.28 million CNY supports its operational flexibility and capacity to fund growth initiatives or return capital to shareholders.

Profitability metrics show a return on equity (ROE) of 10.97% and a return on assets (ROA) of 6.99%, both of which are in line with industry norms for medical equipment and supplies firms. The company's operating margin, derived from an operating income of 271.45 million CNY on revenue of 1.07 billion CNY, reflects a healthy margin profile, though the exact cohort median is not provided for direct comparison.

The company's revenue is concentrated in a single business segment, as disclosed in its financial reporting, with no geographic breakdown provided in the available data. This lack of geographic diversification may expose the company to regional economic or regulatory risks, though the extent of such exposure is not quantified in the available data.

The company's growth trajectory is not explicitly outlined in the available data, but its free cash flow and operating cash flow of 222.28 million CNY and 348.11 million CNY, respectively, suggest a stable cash-generating business. The absence of a detailed outlook for the current or next fiscal year limits the ability to assess near-term growth expectations.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk, with no significant dilution expected in the near term. The risk assessment also notes that the company has negative net cash after subtracting total debt, which may impact its ability to fund operations or investments without external financing.

No recent events, such as filings or transcripts, are provided in the available data to inform the company's strategic direction or operational developments. The absence of such information limits the ability to assess the company's response to market conditions or regulatory changes.

Key takeaways

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.36.
It generates a return on equity of 10.97% and a return on assets of 6.99%, indicating solid profitability.
Free cash flow of 222.28 million CNY supports operational flexibility and potential shareholder returns.
The company's liquidity is characterized as medium, with a current ratio of 1.26.
No significant dilution risk is identified, with shares outstanding remaining unchanged between basic and diluted measures.
The company's geographic and segment exposure is not fully disclosed, limiting visibility into diversification risks.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

HK$34,00

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

HK$2.00B

Net cashⓘ

-HK$716.0M

Current ratioⓘ

1.3

Debt / equityⓘ

0.4

ROAⓘ

7.0%

ROEⓘ

11.0%

Cash conversionⓘ

159.0%

CapEx / revenueⓘ

-10.8%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin25,5 %Above P75

Net Margin20,5 %Above P75

ROE11,0 %Above P75

Capex / Rev-10,8 %Below median

D/E0,36Below median

Cash Conv1,59Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Shanghai INT Medical Instruments Co Ltd Market data — financials · 2026-05-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

1501.HKCanonical

HKEX · HKD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread